Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium and potassium infusion for cardioversion of postoperative atrial fibrillation after CABG
IRCT20180430039488N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of magnesium and Potassium in Atrial fibrillation (AFib) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Cardioversion of postoperative atrial fibrillation after isolated coronary artery bypass graft surgery. Started Nov 2019; status: completed.
02
Drugs
magnesiumPotassium
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20180430039488N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180430039488N2.